Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM 202 in previously treated squamous carcinoma of the anal canal
2018-002070-51Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retifanlimab in anal squamous cell carcinoma (SCCA), sponsored by Incyte. Primary endpoint: Overall response rate. Started Oct 2018; status: completed.
02
Drugs
retifanlimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2018-002070-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002070-51.